Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

NCT03433755 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

259

Enrollment

INDUSTRY

Sponsor class

Stopped Prematurely Discontinued Amgen decision

Conditions

Primary Hypercholesterolemia
Mixed Dyslipidemia

Interventions

DRUG: evolocumab
DRUG: placebo

Sponsor

Amgen